Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-12 of 12 for your search:
Drug:
agatolimod sodium
Find trials that include:
Any drugs shown
Trial Status:
Closed
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Phase I/II Study of CpG 7909 and Trastuzumab (Herceptin) in Women With Metastatic Breast Cancer Refractory to Trastuzumab and Chemotherapy
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CPGI-C005
, CPGI-C005-CPG7909, CPGI-WIRB-20011156, NCI-V02-1697
2.
CPG 7909 in Patients Wih Stage IV Renal Cell Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Completed
Age:
Over 18
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
C010
, CO10, A8501022, NCT00043407
3.
Phase I/II Randomized Study of CpG 7909 in Patients With Stage IB-IVA Cutaneous T-Cell Lymphoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
UCLA-030104201A
, CPGI-C014, CPGI-CPG7909-C014, NCT00091208
4.
Phase I/II Study of CpG 7909, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Patients With CD20+ Recurrent or Refractory Non-Hodgkin's Lymphoma
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Diagnostic, Treatment
Status:
Closed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
MAYO-LS0382
, MAYO-IRB-703-04, NCT00438880
5.
CPG 7909 Injection in Non-Small Cell Lung Cancer
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
C017
, ProMune, CO17, A8501017, NCT00070629
6.
CPG 7909 Injection in Melanoma
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
C023
, CO23, A8501023, NCT00070642
7.
PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
Over 18
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
C016
, CO16, A8501015, NCT00043368
8.
Phase II Pilot Study of a Multipeptide (gp100 Antigen, MAGE-3, and Tyrosinase Peptide) Melanoma Vaccine, Montanide ISA 51 and ISA 51 VG, and CpG 7909 in Patients With Resected Stage IIC, III, or IV Melanoma
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
16 and over
Sponsor:
NCI
Protocol IDs:
LAC-USC-10M033
, LAC-USC-IRB-942010, NCI-6451, 6451, NCT00085189
9.
Phase I Study of CpG 7909 and Rituximab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Phase:
Phase I
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
UCLA-0112032
, CPGI-C004-CPG7909, NCI-G02-2086, NCT00040950
10.
Immunotherapy of HLA-A2 Positive Stage III/IV Melanoma Patients
Phase:
Phase I
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
Other
Protocol IDs:
LUD 2000-018
, NCT00112229
11.
NY-ESO-1 Protein With Montanide and CpG 7909 as Cancer Vaccine in Several Tumors
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Completed
Age:
18 and over
Sponsor:
Other
Protocol IDs:
LUD2003-022;NYU05-120;CUMC9147
, NCT00299728
12.
Phase I Study of CpG 7909 For the Enhancement of Immune Reconstitution in Patients Who Have Undergone Autologous Stem Cell Transplantation
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Closed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
UMN-2003LS014
, UMN-0302M41542, UMN-MT2003-03, NCT00369291
Select All on Page
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute